仅通过筛查和治疗在高收入国家消除丙型肝炎的可行性
该研究建立基于个体的模型刻画高收入国家(加拿大)的丙型肝炎病毒(HCV)流行,评估预防、筛查和治疗组合策略。在当前基于风险筛查的现状下,模型预测2015至2030年慢性丙型肝炎(CHC)所致失代偿期肝硬化、肝细胞癌和肝病相关死亡分别下降79.4%、76.1%和62.1%,但CHC发病率仅下降11.1%。作者结论认为当前基于风险的筛查及后续治疗不足以实现世界卫生组织(WHO)目标。
要点
- 当前基于风险筛查下,2015至2030年CHC发病率仅预测下降11.1%。
- 同期CHC所致失代偿期肝硬化、肝细胞癌和肝病相关死亡分别预测下降79.4%、76.1%和62.1%。
- 作者结论认为当前基于风险筛查及后续治疗不足以实现WHO目标。
核心结论
- 当前基于风险的筛查及后续治疗将不足以实现世界卫生组织(WHO)目标。
- 大幅扩大筛查和治疗后,死亡率目标或可实现,但预防新发CHC病例的目标不太可能达到,凸显制定强化减害策略对消除HCV的重要性。
研究设计与样本
- 研究建立基于个体的模型,刻画一个持续有移民流入的高收入国家(加拿大)的HCV流行。
- 模型考虑了减害、筛查和治疗策略的组合。
- 模型参数从文献估计,并依据历史HCV数据进行校准。
- 研究进行了敏感性分析以评估不确定性。
主要发现
- 在当前基于风险筛查的现状下,模型预测2015至2030年CHC所致失代偿期肝硬化下降79.4%。
- 同期CHC所致肝细胞癌下降76.1%,肝病相关死亡下降62.1%。
- 同期CHC发病率仅下降11.1%。
- 结果对HCV传播率和每年启动治疗人数敏感。
临床怎么用
- 原文未据此给出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Despite the availability of highly effective direct-acting antiviral therapy, chronic hepatitis C (CHC) continues to cause a major public health burden. In many high-income countries, treatment rates have been declining, which was exacerbated by the impact of the COVID-19 pandemic, threatening the ability to meet the World Health Organization (WHO)'s targets for eliminating HCV as a public health threat by 2030. We sought to model the impact of CHC in Canada, a resource-rich country with ongoing immigration from HCV-endemic regions; which relies exclusively on risk-based screening for case identification. APPROACH AND RESULTS: We developed an agent-based model to characterize the HCV epidemic in a high-income country with ongoing immigration. Combinations of prevention such as harm reduction, screening, and treatment strategies were considered. Model parameters were estimated from the literature and calibrated against historical HCV data. Sensitivity analyses were performed to assess uncertainty. Under the current status quo of risk-based screening, we predict the incidence of CHC-induced decompensated cirrhosis, HCC, and liver-related deaths would decrease by 79.4%, 76.1%, and 62.1%, respectively, between 2015 and 2030, but CHC incidence would only decrease by 11.1%. The results were sensitive to HCV transmission rate and an annual number of people initiating treatment. CONCLUSIONS: Current risk-based screening, and subsequent treatment, will be inadequate to achieve WHO goals. With extensive scale-up in screening, and treatment, the mortality target may be achievable, but the target for preventing new CHC cases is unlikely reachable, highlighting the importance of developing enhanced harm-reduction strategies for HCV elimination.
引用
- Tian F, Forouzannia F, Feng Z, et al. Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries. Hepatology. 2024. PMID: 38478751. doi:10.1097/HEP.0000000000000779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。